AstraZeneca (AZN1N) AI Stock Analysis

Company Guidance

For the full year, AstraZeneca continues to expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage; core gross margins are expected to be stable to slightly higher than in 2025, R&D is expected to be at the upper end of the low 20s percentage range, and the core tax rate is expected to be within 18% to 22%. Full year CapEx is now expected to increase by low teens percentage compared to 2025, milestone payments relating to prior BD transactions are expected to be approximately $2.5 billion, other operating income in the second half is expected to be slightly higher than the first half, and operating expenses are expected to show a sequential step-up in the fourth quarter versus third quarter, with finance expenses also expected to be higher in the fourth quarter than in the third quarter. The Reshaping for Sustainable Growth program is expected to incur up to $2 billion in onetime restructuring costs and deliver $1.5 billion in annualized pretax run rate benefits, with activities expected to be completed by the end of 2029; for 2027, the company expects more than 20 high-value trial readouts and pivotal data for 9 potential new medicines, representing more than $20 billion in non-risk-adjusted peak year revenue.